Ginkgo bioworks provides preliminary unaudited 2021 revenue highlights and business review

Boston, jan. 12, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, announced today preliminary performance updates for the year ended december 31, 2021. among the results, ginkgo highlighted that it expects to meet or exceed its key 2021 full year targets for the commencement of new cell programs and revenue from its cell programming and biosecurity offerings based on its preliminary unaudited estimates.
DNA Ratings Summary
DNA Quant Ranking